Search

Your search keyword '"de Klerk, John M. H."' showing total 267 results
Start Over Author "de Klerk, John M. H."
267 results on '"de Klerk, John M. H."'

2. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial

Author

van Dodewaard-de Jong, Joyce M., de Klerk, John M. H., Bloemendal, Haiko J., Oprea-Lager, Daniela E., Hoekstra, Otto S., van den Berg, H. Pieter, Los, Maartje, Beeker, Aart, Jonker, Marianne A., O’Sullivan, Joe M., Verheul, Henk M. W., and van den Eertwegh, Alfons J. M.

Published
2017
Full Text
View/download PDF

10. Performance and Prospects of [ 68 Ga]Ga-FAPI PET/CT Scans in Lung Cancer.

Author

Borgonje, Paula E., Andrews, Louise M., Herder, Gerarda J. M., and de Klerk, John M. H.

Subjects
BRAIN tumor diagnosis, FIBROBLASTS, PREDICTIVE tests, LUNG tumors, RADIOISOTOPES, METASTASIS, GALLIUM isotopes, BONE tumors, RADIOPHARMACEUTICALS, TUMOR markers, DEOXY sugars
Abstract

Simple Summary: The purpose of this review was to provide an overview of all the available evidence regarding the use of fibroblast activation protein inhibitor (FAPI) as a tracer for positron emission tomography (PET) in patients with lung cancer. In several studies and case reports, radioisotope-labelled FAPI PET/CT showed a strong diagnostic performance in lung cancer. In addition, the possible prognostic value of FAPI PET/CT in lung cancer is proposed. Fibroblast activation protein (FAP) could be a promising target for tumor imaging and therapy, as it is expressed in >90% of epithelial cancers. A high level of FAP-expression might be associated with worse prognosis in several cancer types, including lung cancer. FAPI binds this protein and allows for labelling to Gallium-68, as well as several therapeutic radiopharmaceuticals. As FAP is only expressed at insignificant levels in adult normal tissue, FAPI provides a highly specific tumor-marker for many epithelial cancers. In this review, current information on the use of [68Ga]Ga-FAPI PET/CT in lung cancer is presented. [68Ga]Ga-FAPI shows a high uptake (standardized uptake value = SUVmax) and tumor-to-background ratio (TBR) in primary lung cancer lesions, as well as in metastatic lesions of other tumor types located in the lung and in lung cancer metastases located throughout the body. Where a comparison was made to [18F]FDG PET/CT, [68Ga]Ga-FAPI showed a similar or higher SUVmax and TBR. In brain and bone metastases, [68Ga]Ga-FAPI PET/CT outperformed [18F]FDG PET/CT. In addition to this strong diagnostic performance, a possible prognostic value of [68Ga]Ga-FAPI PET/CT in lung cancer is proposed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules.

Author

de Koster, Elizabeth J., Noortman, Wyanne A., Mostert, Jacob M., Booij, Jan, Brouwer, Catherine B., de Keizer, Bart, de Klerk, John M. H., Oyen, Wim J. G., van Velden, Floris H. P., de Geus-Oei, Lioe-Fee, and Vriens, Dennis

Subjects
THYROID nodules, CYTOLOGY, RADIOMICS, CLINICAL trials
Abstract

Purpose: To evaluate whether quantitative [18F]FDG-PET/CT assessment, including radiomic analysis of [18F]FDG-positive thyroid nodules, improved the preoperative differentiation of indeterminate thyroid nodules of non-Hürthle cell and Hürthle cell cytology. Methods: Prospectively included patients with a Bethesda III or IV thyroid nodule underwent [18F]FDG-PET/CT imaging. Receiver operating characteristic (ROC) curve analysis was performed for standardised uptake values (SUV) and SUV-ratios, including assessment of SUV cut-offs at which a malignant/borderline neoplasm was reliably ruled out (≥ 95% sensitivity). [18F]FDG-positive scans were included in radiomic analysis. After segmentation at 50% of SUVpeak, 107 radiomic features were extracted from [18F]FDG-PET and low-dose CT images. Elastic net regression classifiers were trained in a 20-times repeated random split. Dimensionality reduction was incorporated into the splits. Predictive performance of radiomics was presented as mean area under the ROC curve (AUC) across the test sets. Results: Of 123 included patients, 84 (68%) index nodules were visually [18F]FDG-positive. The malignant/borderline rate was 27% (33/123). SUV-metrices showed AUCs ranging from 0.705 (95% CI, 0.601–0.810) to 0.729 (0.633–0.824), 0.708 (0.580–0.835) to 0.757 (0.650–0.864), and 0.533 (0.320–0.747) to 0.700 (0.502–0.898) in all (n = 123), non-Hürthle (n = 94), and Hürthle cell (n = 29) nodules, respectively. At SUVmax, SUVpeak, SUVmax-ratio, and SUVpeak-ratio cut-offs of 2.1 g/mL, 1.6 g/mL, 1.2, and 0.9, respectively, sensitivity of [18F]FDG-PET/CT was 95.8% (95% CI, 78.9–99.9%) in non-Hürthle cell nodules. In Hürthle cell nodules, cut-offs of 5.2 g/mL, 4.7 g/mL, 3.4, and 2.8, respectively, resulted in 100% sensitivity (95% CI, 66.4–100%). Radiomic analysis of 84 (68%) [18F]FDG-positive nodules showed a mean test set AUC of 0.445 (95% CI, 0.290–0.600) for the PET model. Conclusion: Quantitative [18F]FDG-PET/CT assessment ruled out malignancy in indeterminate thyroid nodules. Distinctive, higher SUV cut-offs should be applied in Hürthle cell nodules to optimize rule-out ability. Radiomic analysis did not contribute to the additional differentiation of [18F]FDG-positive nodules. Trial registration number: This trial is registered with ClinicalTrials.gov: NCT02208544 (5 August 2014), https://clinicaltrials.gov/ct2/show/NCT02208544. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

15. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer REPLY : Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer REPLY

Author

van Kalmthout, Ludwig W M, van Melick, Harm E, Lavalaye, Jules, Meijer, Richard P, Kooistra, Anko, de Klerk, John M H, Braat, Arthur J A T, Kaldeway, H Peter, de Bruin, P C, de Keizer, Bart, and Lam, Marnix G E H

Subjects
Urology, Journal Article
Published
2020

16. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer REPLY: Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer REPLY

Author

Researchgr. Nucleaire Geneeskunde, MS Urologische Oncologie, Urologie Medisch volwassenen, Cancer, MS Radiologie, van Kalmthout, Ludwig W M, van Melick, Harm E, Lavalaye, Jules, Meijer, Richard P, Kooistra, Anko, de Klerk, John M H, Braat, Arthur J A T, Kaldeway, H Peter, de Bruin, P C, de Keizer, Bart, Lam, Marnix G E H, Researchgr. Nucleaire Geneeskunde, MS Urologische Oncologie, Urologie Medisch volwassenen, Cancer, MS Radiologie, van Kalmthout, Ludwig W M, van Melick, Harm E, Lavalaye, Jules, Meijer, Richard P, Kooistra, Anko, de Klerk, John M H, Braat, Arthur J A T, Kaldeway, H Peter, de Bruin, P C, de Keizer, Bart, and Lam, Marnix G E H

Published
2020

22. Reply by Authors

Author

van Kalmthout, Ludwike W. M., primary, van Melick, Harm H. E., additional, Lavalaye, Jules, additional, Meijer, Richard P., additional, Kooistra, Anko, additional, de Klerk, John M. H., additional, Braat, Arthur J. A. T., additional, Kaldeway, H. Peter, additional, de Bruin, Peter C., additional, de Keizer, Bart, additional, and Lam, Marnix G. E. H., additional

Published
2020
Full Text
View/download PDF

34. Cytotoxic effects of the therapeutic radionuclide rhenium-188 combined with taxanes in human prostate carcinoma cell lines

Author

Lange, Rogier, Heine, Robter T., Van Wieringen, Wessel N., Tromp, Adrienne M., Paap, Mayke, Bloemendal, Haiko J., De Klerk, John M H, Hendrikse, N. Harry, Geldof, Albert A., Lange, Rogier, Heine, Robter T., Van Wieringen, Wessel N., Tromp, Adrienne M., Paap, Mayke, Bloemendal, Haiko J., De Klerk, John M H, Hendrikse, N. Harry, and Geldof, Albert A.

Published
2017

35. A Phase 1 Trial of Cabazitaxel Combined With 188 Re–Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment : The ReCab Trial

Author

van Dodewaard-de Jong, Joyce M., Bouman-Wammes, Esther W., Bloemendal, Haiko J., Verheul, Henk M W, de Klerk, John M H, van den Eertwegh, Alfons J M, van Dodewaard-de Jong, Joyce M., Bouman-Wammes, Esther W., Bloemendal, Haiko J., Verheul, Henk M W, de Klerk, John M H, and van den Eertwegh, Alfons J M

Published
2017

36. Radiation-Induced Giant Cell Granuloma Mimicking Relapsed Hodgkin Lymphoma at FDG-PET/CT

Author

Onderzoek Beeld, Arts-assistenten Radiologie, Adams, Hugo J.A., de Klerk, John M. H., Regelink, Josien C., Heggelman, Ben G. F., Dubois, Stefan V., Kwee, Thomas C., Onderzoek Beeld, Arts-assistenten Radiologie, Adams, Hugo J.A., de Klerk, John M. H., Regelink, Josien C., Heggelman, Ben G. F., Dubois, Stefan V., and Kwee, Thomas C.

Published
2017

37. A Phase 1 Trial of Cabazitaxel Combined With 188 Re–Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial

Author

MS Medische Oncologie, Cancer, van Dodewaard-de Jong, Joyce M., Bouman-Wammes, Esther W., Bloemendal, Haiko J., Verheul, Henk M W, de Klerk, John M H, van den Eertwegh, Alfons J M, MS Medische Oncologie, Cancer, van Dodewaard-de Jong, Joyce M., Bouman-Wammes, Esther W., Bloemendal, Haiko J., Verheul, Henk M W, de Klerk, John M H, and van den Eertwegh, Alfons J M

Published
2017

38. Cytotoxic effects of the therapeutic radionuclide rhenium-188 combined with taxanes in human prostate carcinoma cell lines

Author

Trialsecretariaat Medische Oncologie, Cancer, Lange, Rogier, Heine, Robter T., Van Wieringen, Wessel N., Tromp, Adrienne M., Paap, Mayke, Bloemendal, Haiko J., De Klerk, John M H, Hendrikse, N. Harry, Geldof, Albert A., Trialsecretariaat Medische Oncologie, Cancer, Lange, Rogier, Heine, Robter T., Van Wieringen, Wessel N., Tromp, Adrienne M., Paap, Mayke, Bloemendal, Haiko J., De Klerk, John M H, Hendrikse, N. Harry, and Geldof, Albert A.

Published
2017

40. Lymphoma grading with FDG-PET/CT readdressed : Direct and timely histopathological correlation study

Author

Adams, Hugo J A, de Klerk, John M H, Fijnheer, Rob, Heggelman, Ben G F, Dubois, Stefan V, Nievelstein, Rutger A J, and Kwee, Thomas C

Subjects
Adult, Aged, 80 and over, Male, Letter, Lymphoma, Research Support, Non-U.S. Gov't, Middle Aged, Prognosis, Young Adult, Fluorodeoxyglucose F18, Positron-Emission Tomography, Humans, Female, Neoplasm Grading, Radiopharmaceuticals, Tomography, X-Ray Computed, Aged, Neoplasm Staging
Published
2016

43. 18F-fluorocholine-PET-CT bij hyperparathyreoïdie

Author

Kluijfhout, Wouter P, Vriens, Menno R, Borel Rinkes, Inne H M, Valk, Gerlof D., de Klerk, John M H, de Keizer, Bart, and Valk, GD

Subjects
Adenoma, Parathyroid Neoplasms, Positron-Emission Tomography, Contrast Media, Humans, Hyperparathyroidism, Primary, Choline
Abstract

18F-fluorocholine PETCT is a new imaging modality for the localization of pathological parathyroid glands in patients with primary hyperparathyroidism. The PETCT is a combination scan that uses both the physiological information from the PET and the anatomical information from the CT. Uptake of the radioisotope 18F-fluorocholine is increased in pathological parathyroid glands. 18F-fluorocholine PETCT helps clinicians to localize the pathological parathyroid glands where conventional modalities fail to do so. This enables surgeons to carry out targeted minimal invasive surgery. It may also prevent the patient having to undergo a more extensive exploration, with its associated risks, and alleviate the necessity of taking medications with side effects. Although the literature on this subject is still scarce, preliminary results are promising. As any hospital with a PETCT can perform the scan, we expect that its use in patients with hyperparathyroidism will increase over the next few years.

Published
2015

44. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging : a multicenter study from the Netherlands

Author

Kluijfhout, Wouter P, Vorselaars, Wessel M C M, van den Berk, Sandra A M, Vriens, Menno R, Borel Rinkes, Inne H M, Valk, Gerlof D, van Dalen, Thijs, de Klerk, John M H, de Keizer, Bart, Kluijfhout, Wouter P, Vorselaars, Wessel M C M, van den Berk, Sandra A M, Vriens, Menno R, Borel Rinkes, Inne H M, Valk, Gerlof D, van Dalen, Thijs, de Klerk, John M H, and de Keizer, Bart

Published
2016

45. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone : A Systematic Review

Author

Jong, Joyce M van Dodewaard-de, Oprea-Lager, Daniela E, Hooft, Lotty, de Klerk, John M H, Bloemendal, Haiko J, Verheul, Henk M W, Hoekstra, Otto S, van den Eertwegh, Alfons J M, Jong, Joyce M van Dodewaard-de, Oprea-Lager, Daniela E, Hooft, Lotty, de Klerk, John M H, Bloemendal, Haiko J, Verheul, Henk M W, Hoekstra, Otto S, and van den Eertwegh, Alfons J M

Published
2016

49. Where Does Diffuse Large B-Cell Lymphoma Relapse?

Author

Adams, Hugo J A, de Klerk, John M H, Fijnheer, Rob, Heggelman, Ben G F, Dubois, Stefan V, Nievelstein, Rutger A J, Kwee, Thomas C, Adams, Hugo J A, de Klerk, John M H, Fijnheer, Rob, Heggelman, Ben G F, Dubois, Stefan V, Nievelstein, Rutger A J, and Kwee, Thomas C

Published
2016

50. Where Does Diffuse Large B-Cell Lymphoma Relapse?

Author

Cancer, Arts-assistenten Radiologie, Other research (not in main researchprogram), Adams, Hugo J A, de Klerk, John M H, Fijnheer, Rob, Heggelman, Ben G F, Dubois, Stefan V, Nievelstein, Rutger A J, Kwee, Thomas C, Cancer, Arts-assistenten Radiologie, Other research (not in main researchprogram), Adams, Hugo J A, de Klerk, John M H, Fijnheer, Rob, Heggelman, Ben G F, Dubois, Stefan V, Nievelstein, Rutger A J, and Kwee, Thomas C

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results